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Peritoneal carcinomatosis is an advanced state of malig-
nancy often arising from gastrointestinal or ovarian
cancers. It is characterized by dissemination of tumors
throughout the peritoneal cavity and is associated with
5-year survival rates less than 25%. Since the peritoneal
cavity is highly enriched with macrophages, we investi-
gated the efficacy of CD47-blocking therapies for perito-
neal carcinomatosis. CD47 is a molecule that is highly
expressed on the surface of many tumors, where it acts as
a myeloid-specific immune checkpoint. By binding to
SIRPa, an inhibitory receptor on macrophages and other
myeloid cells, CD47 is able to transduce inhibitory signals
that prevent macrophage phagocytosis.
We first we assessed the potency of various CD47-
blocking reagents at stimulating phagocytosis in vitro.
Using human macrophages and human colon cancer cells,
we found that CD47-blocking reagents induced phagocy-
tosis in a dose-dependent manner. The high-affinity
SIRPa-Fc fusion proteins[1] induced phagocytosis with
greater potency compared to anti-CD47 antibodies (EC50
0.8351 vs. 4.669 nM, p = 0.0003) or other CD47-blocking
reagents. Using multiplex profiling of 51 cytokines, we
identified a unique cytokine signature that correlated with
macrophage phagocytosis. We next established a xenograft
model of peritoneal carcinomatosis in which mice pro-
gressed to form malignant ascites. When tumor-bearing
mice were treated with CD47-blocking therapies, we
detected a cytokine signature within the tumor microen-
vironment. In particular, MCP-3 was elevated within both
the ascites fluid and serum of tumor-bearing mice after
treatment with high-affinity SIRPa-Fc fusion proteins (p <
0.0001) and may serve as a clinical biomarker of response
to therapy. Last, we investigated the therapeutic efficacy of
CD47-blocking therapies for peritoneal carcinomatosis.
Animals treated with high-affinity SIRPa-Fc fusion pro-
teins exhibited inhibition of tumor growth (p < 0.05) and
prolonged survival (p = 0.0022) relative to control animals.
Since the high-affinity SIRPa-Fc fusion proteins bind both
human and mouse CD47, this model provides insight into
therapeutic efficacy in the setting of an ‘antigen sink’ and
toxicity. The main toxicity observed was a reduction in
hematocrit (41.78% vs. 35.63%, p < 0.001). CD47-blocking
immunotherapies are now undergoing evaluation in
clinical trials. The results of this study suggest potential
benefits of CD47-blocking therapies in advanced stages of
malignancy, such as peritoneal carcinomatosis.
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